FUJIFILM DIOSYNTH BIOTECHNOLOGIES BREAKS GROUND FOR EXPANSION OF ITS MICROBIAL PRODUCTION FACILITY IN THE UNITED KINGDOM
Virtual groundbreaking ceremony celebrates the start of expansion that will triple microbial production capacity
Billingham, United Kingdom, April 1, 2021 — FUJIFILM Diosynth Biotechnologies (FDB), a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors, held a virtual ground-breaking ceremony to mark the start of its Teesside, UK microbial facility expansion. The 9 billion yen ($83M USD) was previously announced in March 2020.
The expansion will triple the facilities current production capacity with a new production line equipped with 2 X 2000L fermenters and a modular purification suite. The utilities at the facility are being upgraded to accommodate for high volume production using a combination of traditional and FDB’s proprietary SymphonX™ technologies.
Present at the ceremony for FUJIFILM Diosynth Biotechnologies were Martin Meeson, Chief Executive Officer, Paul Found, Chief Operating Officer- UK site, Nick Martin, Vice President, Operations- UK site and Peter Large, Executive Director, Strategic Investments. Also in attendance representing PM Group, Steve Taylor, Project Manager.
“FUJIFILM Diosynth Biotechnologies has been a leader in microbial process development and manufacturing since its inception almost 30 years ago,” said Martin Meeson, chief operating officer, FUJIFILM Diosynth Biotechnologies. “Today we continue our commitment to excellence in the delivery of microbial therapeutics in support of our customers.”
The facility expansion will be operational early 2022.
About FUJIFILM Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Teesside, UK, RTP, North Carolina, College Station, Texas, and Hillerød, Denmark. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™ cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation. For more information, go to: www.fujifilmdiosynth.com
About FUJIFILM Holdings Corporation
FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com
Corporate Media Contact:
FUJIFILM Holdings America Corporation